Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

• Published in: Journal of rheumatology Vol. 42; no. 10; p. 1761
• Main Authors: van Vollenhoven, Ronald F, Fleischmann, Roy M, Furst, Daniel E, Lacey, Stuart, Lehane, Patricia B
• Format: Journal Article
• Language: English
• Published: Canada 01.10.2015
• Subjects: Adult; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Patient Safety; Rituximab - adverse effects; Rituximab - therapeutic use; Severity of Illness Index; Time Factors; Treatment Outcome; RHEUMATOID ARTHRITIS; SAFETY; RITUXIMAB

Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to 11 years. Pooled observed case analysis of data from patients with moderate to severe, active RA in a global clinical trial program. As of September 2012, 3595 patients received a mean of 4 courses (range 1...